| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The specific biological target of (E)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (DMPB) has not been definitively established. Based on its reported activity of increasing melanin production, it may interact with proteins or pathways involved in melanogenesis, such as tyrosinase or the cAMP/MITF signaling pathway. However, its primary receptor or enzyme target remains to be elucidated.
|
|---|---|
| ln Vitro |
In vitro, (E)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (DMPB) has been shown to increase melanin production. This activity is typically assessed in cell-based assays using melanocytes or melanoma cell lines where melanin content is measured after compound treatment. The compound is a natural product isolated from ginger and is used as a research tool to study melanogenesis.
|
| ln Vivo |
In vivo activity data for (E)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (DMPB) are not available in the current scientific literature. Its biological effects have primarily been characterized in vitro, and it has not been evaluated in animal models for pharmacological efficacy or pharmacokinetic behavior.
|
| Enzyme Assay |
No specific in vitro enzyme or receptor binding assay protocols have been published for (E)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (DMPB). Standard protocols for assessing melanin production involve treating cultured melanocytes with the compound and measuring the melanin content spectrophotometrically after cell lysis.
|
| Cell Assay |
In vitro cell-based assay protocols for (E)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (DMPB) typically involve using melanocyte or melanoma cell lines. A standard protocol would involve seeding cells in multi-well plates, treating them with varying concentrations of the compound for several days, and then measuring the melanin content. Cell viability is also assessed to ensure that observed effects are not due to cytotoxicity.
|
| Animal Protocol |
No in vivo animal experimental protocols have been specifically established or reported for (E)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (DMPB). The compound is primarily a research tool for in vitro studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of (E)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (DMPB) have not been characterized in any published studies. The compound has a calculated LogP of 1.91, indicating moderate lipophilicity. It is typically soluble in DMSO. Specific PK parameters such as half-life, Cmax, and AUC have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicological properties of (E)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (DMPB) have not been systematically evaluated in any published studies. As a natural product and research chemical, it should be handled with standard laboratory safety precautions. It is not intended for human use.
|
| References |
|
| Additional Infomation |
According to reports, 4-(3,4-dimethoxyphenyl)-3-buten-1-ol has been found in Zingiber montanum and Zingiber purpureum, both belonging to the ginger family, and relevant data are available for reference.
(E)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (DMPB) is a research-grade natural product isolated from Zingiber cassumunar. It is used primarily as a tool to study melanogenesis due to its ability to increase melanin production. It has not entered clinical trials and is not approved for any therapeutic indication. The compound is available exclusively for research purposes. |
| Molecular Formula |
C12H16O3
|
|---|---|
| Molecular Weight |
208.25
|
| Exact Mass |
208.109
|
| CAS # |
69768-97-4
|
| PubChem CID |
6439118
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
367.1±37.0 °C at 760 mmHg
|
| Flash Point |
175.8±26.5 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.554
|
| LogP |
1.91
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
15
|
| Complexity |
191
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=C(C=C1)/C=C/CCO)OC
|
| InChi Key |
HJXARZMWFOEQTO-HWKANZROSA-N
|
| InChi Code |
InChI=1S/C12H16O3/c1-14-11-7-6-10(5-3-4-8-13)9-12(11)15-2/h3,5-7,9,13H,4,8H2,1-2H3/b5-3+
|
| Chemical Name |
(E)-4-(3,4-dimethoxyphenyl)but-3-en-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8019 mL | 24.0096 mL | 48.0192 mL | |
| 5 mM | 0.9604 mL | 4.8019 mL | 9.6038 mL | |
| 10 mM | 0.4802 mL | 2.4010 mL | 4.8019 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
